Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

Stock Quote Disclaimer: Copyright © 1998-2002 MarketWatch.com Inc. User agreement applies. Historical and current end-of-day data provided by Interactive Data Corp. Intraday data is at least 20-minutes delayed. All times are EDT. Intraday data provided by S&P Comstock and subject to terms of use.

NYSE | BMY 22.07 | -0.02 | 4:01 PM EST | 16 Jan 2009

Top Story

Learn More about Hepatitis B
In the United States, one out of every ten Asian Americans is chronically infected with hepatitis B.

Read more >>


View Our Pharm D Fellowships We partner with Rutgers University to foster growth and development of new pharmacists in a variety of areas throughout our company.
Read more >>

Light to Unite
on World AIDS Day By combining HIV prevention with access to treatment, we can virtually eliminate new HIV infections in 30 years.
Read more >>

Latest News
01.16.2009>>Bristol-Myers Squibb To Announce Results For The Fourth Quarter And Full Year Of 2008 On January 27 01.13.2009>>Bristol-Myers Squibb to Present at Healthcare Conference 01.12.2009>>Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound